{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:59:07Z","timestamp":1787900347895,"version":"build-2784847793"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40261-019-00759-8","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T20:14:54Z","timestamp":1551298494000},"page":"407-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Paliperidone Long-Acting Injections in Huntington\u2019s Disease for Motor and Behavioural Disturbances"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-2739","authenticated-orcid":false,"given":"Nameer","family":"van Oosterom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Theodoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"759_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/currents.rrn1260","author":"J-M Burgunder","year":"2011","unstructured":"Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An International survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s Disease. PLoS Curr. 2011. \n                    https:\/\/doi.org\/10.1371\/currents.rrn1260\n                    \n                  .","journal-title":"PLoS Curr"},{"issue":"1","key":"759_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, Beglinger LJ, O\u2019Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry. 2008;20(1):1\u20133. \n                    https:\/\/doi.org\/10.3109\/10401230701844802\n                    \n                  .","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"759_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","volume":"26","author":"GT Johnston","year":"2011","unstructured":"Johnston GT. Risperidone long-acting injection and Huntington\u02bcs disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26(2):114\u20139. \n                    https:\/\/doi.org\/10.1097\/YIC.0b013e3283407775\n                    \n                  .","journal-title":"Int Clin Psychopharmacol"},{"key":"759_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnins.2013.00114","volume":"7","author":"J Chen","year":"2013","unstructured":"Chen J, Wang E, Cepeda C, Levine M. Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci. 2013;7:7. \n                    https:\/\/doi.org\/10.3389\/fnins.2013.00114\n                    \n                  .","journal-title":"Front Neurosci."},{"key":"759_CR5","unstructured":"Invega Sustenna. eMIMS. 2018. \n                    https:\/\/www.mimsonline.com.au\/Search\/Search.aspx\n                    \n                  ."},{"issue":"2","key":"759_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-McLeod","year":"2015","unstructured":"Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R&D. 2015;15(2):163\u201374. \n                    https:\/\/doi.org\/10.1007\/s40268-015-0092-x\n                    \n                  .","journal-title":"Drugs R&D"},{"key":"759_CR7","unstructured":"Invega Trinza. eMIMS. 2018. \n                    https:\/\/www.mimsonline.com.au\/Search\/Search.aspx\n                    \n                  ."},{"issue":"5","key":"759_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372. \n                    https:\/\/doi.org\/10.1177\/0004867416641195\n                    \n                  .","journal-title":"Aust N Z J Psychiatry"},{"key":"759_CR9","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"TRE Barnes","year":"2018","unstructured":"Barnes TRE, Taylor DM, Young AH. The Maudsley prescribing guidelines in psychiatry. Newark: Wiley; 2018."},{"issue":"1","key":"759_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hup.655","volume":"20","author":"HY Jung","year":"2005","unstructured":"Jung HY, Kim JH, Ahn YM, Kim SC, Hwang SS, Kim YS. Liverpool university neuroleptic side-effect rating scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Human Psychopharmacol Clin Exp. 2005;20(1):41\u20135. \n                    https:\/\/doi.org\/10.1002\/hup.655\n                    \n                  .","journal-title":"Human Psychopharmacol Clin Exp"},{"issue":"3","key":"759_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0269881107087976","volume":"22","author":"L Waddell","year":"2008","unstructured":"Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238\u201343. \n                    https:\/\/doi.org\/10.1177\/0269881107087976\n                    \n                  .","journal-title":"J Psychopharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00759-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00759-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00759-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T19:25:36Z","timestamp":1582745136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00759-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00759-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"27 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that no source of funding was obtained for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Theo Theodoros has attended educational events organised by Jannsen: Pharmaceutical Companies of Johnson & Johnson (where expenses were paid).\u00a0Nameer van Oosterom has not conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was also approved by the Metro South Human Research Ethics Committee (reference number: HREC\/18\/QPAH\/87).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A\u00a0waiver of consent was granted for this project by the Metro South Human Research Ethics Committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}